Global Healthcare Market and Growth Strategy
Disclaimer
The information contained in this Investor Presentation is for your confidential use only and is presented solely for the purpose of
allowing you to evaluate the securities and is not to be used for any other purpose or made available to anyone else. Distribution of
this Investor Presentation by you to any person is unauthorized and any disclosure of this Investor Presentation, in whole or in part,
by or to any person in any medium whatsoever, without the prior written consent of the Company is prohibited.
Forward-Looking Statements
Certain statements contained in this Investor Presentation may constitute "forward-looking statements". All statements, other than
statements of historical fact, in this document that address activities, events or developments that the Company or a third party
expects or anticipates will or may occur in the future, including future results, performance, achievements, prospects or
opportunities for the Company, and may include statements regarding the financial position, budgets, litigation, projected costs,
capital expenditures, financial results, taxes, plans and objectives of, or involving, the Company. Such forward-looking information in
some cases, can be identified by terminology such as "may", "might", "will", "could", "should", "would", "occur", "expect", "plan",
"anticipate", "believe", "intend", "seek", "aim", "estimate", "target", "project", "predict", "forecast", "potential", "continue", "likely",
"schedule", "potentially" or the negative thereof or other similar expressions concerning matters that are not historical facts.
Forward-looking information in this Investor Presentation may include, but is not limited in any manner to statements with respect
to: business goals and strategy; estimates regarding increased global healthcare expenditure; expectations regarding the ability of
our solutions to benefit the patient experience, assist healthcare providers in providing better care, and lowering organizations'
costs of developing and maintaining content; expectations regarding the ability of our analytics to deliver better financial outcomes
at all levels of care; the Clinic 360, MD BriefCase and HealthCare Plus acquisitions (the "Acquisition"); expectations regarding
synergies resulting from the Acquisitions; expectations regarding the timely completion and success of the Acquisitions, including
the combination's ability to maximize billing, address critical gaps in primary care, increase cross-sell opportunities and offer new
and innovative digital care solutions to patient and client networks; expectations regarding the impact of the COVID-19 pandemic
on operations; expectations regarding the timing and manner of economic recovery following the COVID-19 pandemic; projected
financial position including forecasted revenue for the Company and the Acquisitions for the fiscal year 2021 and 2022, projected
gross profit and gross margin for the Company and the Acquisitions for the fiscal year 2021 and 2022 and EBITDA and EBITDA
margin projections for the fiscal year 2021 and 2022; expectations regarding the use of our solutions and technologies in
healthcare systems; expectations regarding our ability to enter new jurisdictions; expectations regarding the acceptance of our
products and solutions by the market; our ability to secure and maintain partnerships with electronic medical records (EMR)
vendors, content providers, delivery partners and complementary technology vendors; plans for expansion and growth, including
our ability to acquire organizations that enhance our portfolio;; and the financial position of peer companies in global healthcare
technology, including estimates regarding their expected total enterprise value in CY2021 and 2022; and expectations regarding
our technology's efficacy.
Material factors and assumptions used by management of the Company to develop the forward-looking information include, but are
not limited to: COVID-19 does not materially shift the long-term strategic priorities of prospective and existing customers over the
next two fiscal years; the Company does not experience material delays in accounts receivable over the next two fiscal years; the
global political climate does not change the purchasing patterns of current and prospective international clients; the Company's
solutions remain accessible to existing and potential customers 24 hours a day, seven days a week, without interruption or
degradation of performance, over the next two fiscal years; the Company's solutions evolve in lockstep with market demands for
clinical decision support, connectivity tools and clinical services over the next two fiscal years.
Material factors and assumptions used by management of the Company to develop the forward-looking information include, but are
not limited to: COVID-19 does not materially shift the long-term strategic priorities of prospective and existing customers over the
next two fiscal years; the Company does not experience material delays in accounts receivable over the next two fiscal years;
the global political climate does not change the purchasing patterns of current and prospective international clients; the Company's
solutions remain accessible to existing and potential customers 24 hours a day, seven days a week, without interruption or
degradation of performance, over the next two fiscal years; the Company's solutions evolve in lockstep with market demands
for clinical decision support, connectivity tools and clinical services over the next two fiscal years;; beta-testing of Company
solutions in Health Care Plus and Clinic 360 clinics reduces time of product iteration and increases product margin over the next two
fiscal years; the evolution of the Company's solutions over the next two fiscal years enables the Company to enter new jurisdictions
with enhanced product suite; the evolution of the Company's solutions over the next two fiscal years enhances product stickiness
and eases retention of its current client base; current Company product offerings are consolidated in FY2021 to include only
integrated solutions, reducing unnecessary spend; HealthCare Plus re-opens two of its currently closed brick-and-mortar clinics
during FY2021; the Company pipeline of global EMR/HIS partners continues to grow over the next two fiscal years; the Company's
direct sales pipeline evolves to include opportunities related to clinical services (e.g. growth of in-person & virtual clinic presence)
over the next two fiscal years; the Company is able to participate in a wider range of procurement opportunities that include clinical
services, thereby increasing the size and diversification of the sales pipeline; the Company's sales cycle is shortened due to global
EMR/HIS partners and related partnerships with clinical best practice organizations, the impact of which will be most notably
realized in FY 2022; the Company's sales cycle is shortened due to product readiness testing performed in HCP clinics, the impact
of which is most notably realized in FY 2022; SaaS license fees driven by sales of the Company's solutions account for the majority
of revenues for FY 2021 & FY 2022; the Company retains its current base of skilled employees and hires to fill gaps related to
market demands over the next two fiscal years; there being no material adverse changes to the access and cost of open software
products developed by third parties that are utilized by the Company; and there being no material variations in the legislation and
regulation of health care and health care professionals in Canada and the regulation of electronic medical records as it affects the
business of the Company.
Although management of the Company believes that the expectations reflected in such forward-looking statements are reasonable
and represent the Company's internal projections, expectations and beliefs at this time, such statements involve known and
unknown risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts,
predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives,
strategic goals and priorities will not be achieved. A variety of factors, many of which are beyond the Company's control, may affect
the operations, performance and results of the Company, and could cause actual results in future periods to differ materially from
current expectations of estimated or anticipated events or results expressed or implied by such forward-looking statements. Such
factors include, among other things, the risks described at "Risk Factors". This Investor Presentation may also contain
future-oriented financial information ("FOFI") and information which could be considered to be in the nature of a "financial outlook".
Such FOFI or financial outlook was approved by the Company for the purpose of providing the Company's reasonable estimate of
what return investors might expect to earn based on the assumptions set forth in such estimates.
The Company cautions that such FOFI or financial outlook reflects the Company's current beliefs and is based on information
currently available to the Company and on assumptions the Company believes are reasonable. The Company's actual financial
position and results of operations may differ materially from management's current expectations and, as a result, the Company's
revenue, EBITDA and expenses may differ materially from the revenue, EBITDA and expenses profiles provided in the FOFI or
financial outlook as they are subject to a number of significant risks and uncertainties.
Certain of these risks and uncertainties are beyond the Company's control. Consequently, all of the FOFI or financial outlook are
qualified by these cautionary statements, and there can be no assurances that the actual results or developments will be realized or,
even if substantially realized, that they will have the expected consequences to, or effect on, the Company.
Investors are cautioned against placing undue reliance on forward-looking statements.
thinkresearch
TSXV: THNK
2View entire presentation